Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RELMADA THERAPEUTICS, INC. Director's Dealing 2020

Apr 9, 2020

34465_dirs_2020-04-09_3a53d786-7891-4fc7-8625-28f90bb6e4b1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2020-04-09

Reporting Person: SCHMIDT ERIC THOMAS (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-04-09 Common Stock X 32500 $6.00 Acquired 87500 Direct
2020-04-09 Common Stock X 12500 $9.00 Acquired 100000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-04-09 Warrants to purchase common stock $6.00 X 32500 Disposed 2023-12-03 Common Stock (32500) Direct
2020-04-09 Warrants to purchase common stock $9.00 X 12500 Disposed 2024-05-14 Common Stock (12500) Direct